Undisclosed siRNA Program(s)
Rare Genetic Disorders (Autosomal Dominant)
Pre-clinicalActive
Key Facts
Indication
Rare Genetic Disorders (Autosomal Dominant)
Phase
Pre-clinical
Status
Active
Company
About Loto Biotech
LOTO Biotech is a private, preclinical-stage biotech company pioneering an AI-driven platform for the design of siRNA therapeutics targeting rare genetic disorders. Founded by internationally recognized scientists, the company aims to silence disease-causing genes with high specificity, initially focusing on autosomal dominant conditions where silencing the mutated allele can restore health. Its mission is driven by a patient-centric approach, seeking to deliver scalable therapeutic solutions for conditions with high unmet need. The company is currently in the platform and candidate discovery phase, positioning itself in the rapidly growing RNA therapeutics space.
View full company profile